Jeremy Grantham Vanda Pharmaceuticals Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$15.69 - $21.14 $205,539 - $276,934	-13,100 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$15.35 - $21.27 $201,085 - $278,637	13,100 New	13,100 $225,000
Q1 2021 May 13, 2021	SELL	$13.42 - $20.28 $195,932 - $296,088	-14,600 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$9.77 - $13.81 $1.2 Million - $1.69 Million	-122,700 Reduced 89.37%	14,600 $192,000
Q3 2020 Nov 13, 2020	SELL	$9.32 - $12.02 $273,076 - $352,186	-29,300 Reduced 17.59%	137,300 $1.33 Million
Q2 2020 Aug 13, 2020	BUY	$9.66 - $12.02 $1.42 Million - $1.76 Million	146,600 Added 733.0%	166,600 $1.91 Million
Q1 2020 May 14, 2020	BUY	$7.5 - $16.8 $150,000 - $336,000	20,000 New	20,000 $207,000

161

45.2M

165K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $282M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.